Completed PHASE1 INTERVENTIONAL 8-arm NCT00691210

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies (SAHA)

Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies

Sponsor: Columbia University

Conditions Hodgkin's Disease Non-Hodgkin's Lymphoma

Interventions Etoposide Niacinamide Vorinostat

Updated 9 times since 2017 Last updated: Nov 5, 2020 Started: Jun 30, 2008 Primary completion: Feb 28, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hodgkin's Disease and Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by Columbia University and has accumulated 9 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Dec 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jun 2019 — Dec 2020 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Columbia University
Merck Sharp & Dohme LLC

Data source: Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States